PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Sarpagandha Ghana vati (500 mg twice daily for 30 days) was evaluated for efficacy in managing essential hypertension [PMID:29242090]. Sarpagandha Vati helped in reducing systolic and diastolic pressures, although it was found less effective than Shirodhara in one trial [PMID:22048535].
The plant is described as a safe and effective treatment for hypertension, though its popularity declined due to associated adverse effects [PMID:26770146].
Sarpagandha ghanvati is a classical Ayurvedic formulation widely prescribed for anxiety and insomnia [PMID:26798180, PMID:30558695].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 35819514 (2022) — Biotechnological interventions and indole alkaloid production in Rauvolfia serpentina. · Applied microbiology and biotechnology
- 2.PMID: 26770146 (2015) — Rauwolfia in the Treatment of Hypertension. · Integrative medicine (Encinitas, Calif.)
- 3.PMID: 31363825 (2019) — Biotechnological interventions on the genus Rauvolfia: recent trends and imminent prospects. · Applied microbiology and biotechnology
- 4.PMID: 26798180 (2015) — Design, Development and Rationalization of Sarpagandha Ghanvati. · Indian journal of pharmaceutical sciences
- 5.PMID: 17722843 (2007) — [Milestones of cardiovascular therapy. IV. Reserpine].